ACTRN12616001473459已完成未知
An additional Saturday allied health service for Geriatric Evaluation and Management to reduce patient length of stay and increase functional independence
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 50 Years 至 o limit（—）
- 性别
- All
入选标准
- •All patients admitted for Geriatric Evaluation and Management in the two participating wards during the data collection phase
排除标准
- •1. Patients not admitted under Geriatric Evaluation and Management (e.g. for Transition Care Program).
- •2. Patients admitted prior to the data collection phase will be excluded.
- •3. Patients readmitted to Geriatric Evaluation and Management after a previous Geriatric Evaluation and Management admission during the data collection phase will be considered to have been admitted during the initial admission.
研究者
相似试验
已完成
不适用
Evaluation of weekend allied health services on acute medical / surgical wardsACTRN12613001231730Department of Health, Victoria7,300
尚未招募
不适用
Effect of adding back package to he primary careIRCT20200707048039N1Tehran University of Medical Sciences9,440
已完成
不适用
Do additional allied health services for rehabilitation reduce length of stay without compromising patient outcomes?ACTRN12609000973213icholas Taylor712
进行中（未招募）
1 期
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002637-42-DECB Biopharma SR300
进行中（未招募）
1 期
A study to test the safety and tolerability of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002637-42-PLCB Biopharma SR300